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Received February 2, 2010; accepted August 21, 2010AbstractWe report a case of extensive paranasal sinus and orbit rhabdomyosarcoma (RMS) with intra-cranial invasion treated successfully with
chemotherapy and radiotherapy. A 13-years-old male patient complained of painless and progressive proptosis of his left eye for two weeks.
Ocular examination showed elevated intraocular pressure, limited extraocular movement, proptosis, and conjunctival ciliary injection in the left
eye. Brain CT and MRI demonstrated a large enhancing soft tissue mass lesion with bone destruction involving left ethmoid sinus, nasal cavity,
maxillary sinus, and orbital cavity with crossing of the midline to the right ethmoid sinus, nasal cavity, and intra-cranial invasion across the
frontal base. The pathology of tumor biopsy revealed rhabdomyosarcoma, alveolar type. Systemic survey showed no evidence of distant
metastasis. Then, the patient received combined radiochemotherapy with Taiwan Pediatric Oncology Group Rhabdomyosarcoma 2007 High-risk
Treatment Protocol. No light perception in his left eye with optic disc atrophy was noted at the beginning of radiotherapy. After 44 weeks of
combined radiochemotherapy, the tumor regressed, and no recurrence has been noted until now. In young patients with sudden-onset proptosis,
RMS should be considered, and early diagnosis is crucial due to more effective prognosis with current radiochemotherapy protocol.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma in childhood. The annual incidence is approximately
4.5 cases per million in children under the age of 20.1 RMS can
arise from striated skeletal muscle and other locations where
skeletal muscle is not typically found. All patients with alveolar
RMS have a poor prognosis, with a median survival time of
17mo. Intracranial extension and an age greater than 10 yrswere
also associated with an unfavorable outcome.2 Here, we report
a case of paranasal sinus and orbit RMS with intra-cranial
invasion presenting with initially rapid proptosis treated* Corresponding author. Dr. Youn-Shen Bee, Department of Ophthalmology,
Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung
813, Taiwan, ROC.
E-mail address: ysbee@vghks.gov.tw (Y.-S. Bee).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.01.031successful with chemotherapy and radiotherapy for about one
year. Current treatment in Taiwan is also discussed.
2. Case report
A 13-year-old male Chinese complained of painless and
progressive proptosis of his left eye for two weeks. He denied
any ocular history, trauma history, or systemic disease. In
ocular examination, his best corrected visual acuity (BCVA)
was 6/5 OD and 6/6 OS. The intraocular pressure (IOP) was
16 mmHg OD and 28 mmHg OS. Exophthalmometry revealed
16 mm OD and 22 mm OS, respectively, and limited extra-
ocular movement (EOM) was noted. Timolol-XE 0.5% QD
OS was prescribed, and brain computed tomography scan
(CT) was arranged immediately.
Brain CT demonstrated a large enhancing soft tissue mass
lesion with bone destruction involving the left ethmoid sinus,hinese Medical Association. All rights reserved.
Fig. 1. (A) Brain computed tomography demonstrated a large soft tissue mass lesion involving the left paranasal sinus, nasal cavity, and orbital cavity with crossing
of the midline to the right paranasal sinus and nasal cavity. (B) Brain magnetic resonance imaging axial view, coronal view, and sagittal view revealed obvious
intracranial extension with cribriform plate destruction to bilateral frontal base regions.
Fig. 2. (A) (B) In hematoxylin and eosin stain, there were many high nuclear/cytoplasmic ratio small blue round cells along connective tissue strands. (C) Muscle-
specific Actin stain and (D) skeletal muscle specific MyoD1 stain were positive.
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orbital cavity with crossing of the midline to involve the right
ethmoid sinus, right frontal sinus and right nasal cavity. It also
revealed intracranial extension with cribriform plate destruc-
tion to bilateral frontal base regions (Fig. 1A). Brain magnetic
resonance imaging (MRI) showed a similar result (Fig. 1B).
Trans-nasal tumor biopsy was performed. In hematoxylin
and eosin (H&E) stain, there were many high nuclear/cyto-
plasmic ratio small blue round cells along connective tissue
strands. Muscle-specific Actin stain and skeletal muscle
specific MyoD1 stain were positive (Fig. 2). Hence, the
pathology result was rhabdomyosarcoma, alveolar type.
Systemic survey including CT for neck, chest, and abdomen,
T-spine MRI, bone scan, lumbar puncture, and abdominal
ultrasound showed no evidence of lymph node metastasis or
distant metastasis. The patient belonged to stage 3 by TNM
staging system and clinical group III by Intergroup rhabdo-
myosarcoma study group (IRSG) clinical grouping system.3,4Table 1
TPOG RMS 2007 high-risk protocol with radiotherapy for totally 50.4 Gy in
cyclophosphamide) for a total of 44 weeks of treatment course
TPOG RMS 2007 High-risk treatment e VAC alone
1. Includes all patients with non-parameningeal primaries and patients with param
without evidence of intracranial extension, base of skull erosion, or cranial nerv
2. Includes all patients with parameningeal tumors with any of the following: (1) ev
spinal cord compression, OR (2) any patient requiring EMERGENCY RT OR
3. Patients with evidence of intracranial extension (touch, displace, invade, distort
should have VAC chemotherapy and begin RT at week 0.
4. Patients with evidence of parameningeal tumors þ any of the following: (1) sk
(displace or indent dura, compress brain parenchyma) OR (4) any patients with
chemotherapy and begin RT at week 15.
Week 0 1 2 3 4 5
V V V V V V
Aþ e e Aþ e e
C e e C e e
) RT (start day 0) /
Induction week 6 7 8 9 10 11 12 13 14
V V V V V V V V E
A e e A e e A e V
C e e C e e C e A
L
Continuation week 26 27 28 29 30 31 32 33 34
V V e V e e V V V
A e e A e e A e e
C e e C e e C e e
VAC (VCR max. 2 mg, AMD max. 2.5 mg, Cyc no max. limits).
V: vincristine 1.5 mg/m2 iv.
A: actinomycin D 0.045 mg/kg iv 5 min one dose.
C: cyclophosphamide 2.2 g/m2 IV 30 min.
Mesna: 60% of Cyc, either 20% at hr 0,4,8 or 60% CI 8 hr will do.
Age VCR dose AMD dose
3 yr 1.5 mg/m2 iv push 0.045 mg/kg
1 yr and <3 yr 0.5 mg/kg2 iv push 0.045 mg/kg
<1 yr 0.025 mg/m2 iv push 0.025 mg/kgAfter complete work-up, the patient was enrolled in the
Taiwan Pediatric Oncology Group Rhabdomyosarcoma 2007
High-risk Treatment Protocol (TPOG RMS 2007 high-risk
protocol) for combined radiochemotherapy. He was enrolled in
the high-risk protocol due to parameningeal tumors with
evidence of base of skull erosion and intracranial extension.
This protocol includes radiotherapy of totally 50.4 Gy in 28
fractions and chemotherapy with VAC (vincristine þ
actinomycin þ cyclophosphamide) for a total of 44 weeks’
treatment course (Table 1).
The patient’s visual acuity in left eye decreased to no light
perception, and left optic atrophy was noted at the beginning
of treatment. His left eye proptosis subsided, and follow-up
brain CT after 39 wks of treatment revealed regression of the
mass lesion (Fig. 3). After the complete 44-wk treatment
course, no grade 3 or grade 4 non-hematologic laboratory
abnormalities developed, and no recurrence has been noted
as of one year after treatment. The TPOG RMS 2007 high-28 fractions and chemotherapy with VAC (vincristine þ actinomycin þ
eningeal primaries, stage 4 alveolar (any age) or embryonal 10 yr of age
e palsy.
idence of base of skull erosion, cranial nerve palsy, or intracranial extension or
(3) physician’s preference selection of VAC Alone Regimen.
, or signal abnormality of dura) OR any patient requiring EMERGENCY RT
ull base erosion, OR (2) cranial nerve palsy, OR (3) metastatic skull disease
paraspinal tumors that touch or displace the cord, should have VAC
15 16 17 18 19 20 21 22 23 24 25
V V V V V e e e V V V E**
e e e e e e e e A e e V
e C e e C e e e C e e A
) XRT (week 15e22) / L
35 36 37 38 39 40 41 42 43 44
V e e V V e V e e E**
A e e A e e A e e V
C e e C e e C e e A
L
Cyc dose
2 one dose iv 2.2 gm/m2 iv 30 min
2 one dose iv 73 gm/kg2 iv 30 min
2 one dose iv 36 gm/kg2 iv 30 min
Fig. 3. Brain computed tomography after 39 weeks of treatment revealed the
regression of the soft mass lesion.
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and informed consent was obtained from patient and his
parents.
3. Discussion
RMS is the most common soft tissue sarcoma and the most
common primary orbital malignancy in childhood. The annual
incidence is approximately 4.5 cases per million in children
under the age of 20.1 Among all areas in the body, the head
and neck region is the most frequent site, accounting for
35e40% of cases.4 Among RMS of the head and neck in
children, orbit accounts for 16%, and paranasal sinuses
account for 10%.5 Due to their close proximity to the skull
base and central nervous system, tumors in paranasal sinuses,
infratemporal fossa, nasal cavity, middle ear, and nasopharynx
are defined as parameningeal tumors.6 In nonmetastatic RMS,
parameningeal tumor belongs to stage 2 or 3 and orbital tumor
belongs to stage 1. The survival rate of RMS from para-
meningeal site is poorer than that from RMS from orbit.7
RMS from paranasal sinuses often presents with paranasal
sinuses swelling, pain, proptosis, epistaxis, sinusitis, obstruc-
tion, and cranial nerve palsies.8 They are often advanced and
locally invasive when the definite diagnosis is made,9 and the
same situation was seen in our patient.
There are several major histology subtypes in RMS.
Embryonal subtype accounts for nearly 70%, with better prog-
nosis, and alveolar subtype accounts for more than 20% with,
a relatively poor prognosis.7 RMS involving the head or neck is
the most common embryonal types, but recent studies revealed
that sinonasal RMS is the predominant alveolar subtype.10
Hence, sinonasal RMS has poor prognosis probably due to the
difficulty of surgical resection and alveolar histology.
In recent years, the survival rate of RMS has greatly
improved with the multimodal therapy proposed by the Inter-
group Rhabdomyosarcoma Study Group (IRSG). In non-
metastatic RMS, the estimated 5-yr overall survival rate was
88% in embryonal type and 72% in alveolar type.7 Multimodal
therapies include combined surgery, chemotherapy, andradiotherapy. If a complete resection is possible, surgical
removal of tumor with subsequent radiochemotherapy is sug-
gested. Due to the impossibility of complete resection, our
patient received combined radiochemotherapy.
Most RMS patients in Taiwan are enrolled in the ongoing
TPOG RMS 2007 protocol. Patients are allocated to low-risk/
intermediate-risk/high-risk group based on age, primary site,
TNM stage, IRSG clinical grouping, lymph node status, and
histology. Our patient belonged to the high-risk group due to
parameningeal tumors with evidence of base of skull erosion
and intracranial extension. His mass lesion regressed, and no
recurrence was noted for one year.
Due to the multimodal therapy, RMS patients have a better
prognosis than before. Hence, the early diagnosis of RMS is
crucial due to the more effective current treatment protocol.
Especially when a young patient presents with rapid unilateral
proptosis, we should keep in mind the possibility of RMS.
We have presented a rare case of alveolar-type paranasal sinus
and orbit RMS with intra-cranial invasion treated successfully
with radiochemotherapy. Although his visual acuity in left eye
was no light perception after initial radiotherapy, the tumor
regressed without relapse for one year after the complete 44-wk
treatment course. No grade 3 or grade 4 non-hematologic labo-
ratory abnormalities developed during the treatment course. The
long-term follow up and investigation is crucial.References
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